Valuable Targets

Cystic Fibrosis Treatment Drug - CFTR Modulators

17 September 2023
5 min read

Cystic Fibrosis (CF) is a multisystem autosomal recessive disease, caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. The CFTR protein is an ion channel mainly used to regulate the transepithelial movement of anions in mucus secretion tissues, thereby coordinating the balance of salt and fluid levels in mucus secretions. Pathogenic mutations in this gene leading to CF can affect multiple organs including the intestines, pancreas, and liver, with the dysfunction of CFTR in the airways particularly detrimental to CF patients. Dehydration of airway surface liquid and thickening of mucus secretions hinder effective airway mucociliary clearance, providing fertile ground for harmful bacteria and leading to repeated infections throughout a patient's life.

CFTR Competitive Landscape

According to the data provided by Patsnap Synapse-Global Drug Intelligence Database: the following figure shows that as of 10 Sep 2023, there are a total of 87 CFTR drugs worldwide, from 69 organizations, covering 27 indications, and conducting 316 clinical trials.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target.

The analysis of the target CFTR reveals a competitive landscape with Vertex Pharmaceuticals, Inc. leading in terms of company growth and R&D progress. Cystic Fibrosis is the primary indication for drugs under this target, with several drugs approved and ongoing research in Preclinical and Inactive stages. Small molecule drugs are progressing rapidly, indicating intense competition in this area. 

The United States is at the forefront of CFTR-related drug development, followed by the European Union and other countries. Overall, the target CFTR shows promising potential for the development of treatments for CFTR-related conditions, with ongoing research and development efforts by various companies and countries.

CFTR Modulators Entering Phase III Clinical Trials: Vanzacaftor

Vanzacaftor is a small molecule drug developed by Vertex Pharmaceuticals, Inc. It falls under the therapeutic areas of congenital disorders, digestive system disorders, and respiratory diseases. The drug specifically targets CFTR, which stands for Cystic Fibrosis Transmembrane Conductance Regulator.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

Vanzacaftor is being developed as a potential treatment for CF. It is currently in Phase 3 of clinical development, which indicates that it has already undergone extensive testing in preclinical and early clinical trials. Phase 3 trials involve a larger number of participants and aim to evaluate the drug's safety and efficacy in a real-world setting.

As a small molecule drug, Vanzacaftor is likely to be orally administered. Small molecules are typically designed to interact with specific targets within cells, such as proteins or enzymes, to modulate their activity. In the case of Vanzacaftor, it is designed to target CFTR and potentially restore its function or improve its activity.

Vertex Pharmaceuticals, Inc. is the originator organization behind Vanzacaftor. They are a renowned pharmaceutical company specializing in the development of innovative therapies for serious diseases, including CF. With their expertise and resources, Vertex Pharmaceuticals is dedicated to advancing the treatment options available for patients with CF.

In summary, Vanzacaftor is a small molecule drug developed by Vertex Pharmaceuticals, Inc. It targets CFTR and is being developed as a potential treatment for Cystic Fibrosis. The drug falls under the therapeutic areas of congenital disorders, digestive system disorders, and respiratory diseases. Currently in Phase 3 of clinical development, Vanzacaftor holds promise for improving the lives of individuals affected by CF.

CFTR Modulators Entering Phase II Clinical Trials:ABBV-119

ABBV-119 is a small molecule drug that is being developed for the treatment of CF. The drug targets the CFTR protein, which is responsible for regulating the movement of salt and water in and out of cells.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

Currently, ABBV-119 is in Phase 2 of clinical development, which means that it has already undergone initial testing in humans to evaluate its safety and efficacy. Phase 2 trials typically involve a larger number of participants and aim to further assess the drug's effectiveness and side effects. This phase is crucial in determining whether the drug has the potential to be a viable treatment option for CF patients.

The therapeutic areas of ABBV-119 include Congenital Disorders, Digestive System Disorders, and Respiratory Diseases. This suggests that the drug may have the potential to address not only CF but also other conditions related to these therapeutic areas. However, it is important to note that the drug's primary indication is for the treatment of CF.

As a small molecule drug, ABBV-119 is likely to have a different mechanism of action compared to biologic drugs. Small molecules are typically orally available and can be easily synthesized, making them more convenient for patients and potentially more cost-effective. However, they may also have limitations in terms of specificity and potency compared to biologics.

In summary, ABBV-119 is a small molecule drug that is currently in Phase 2 of clinical development for the treatment of Cystic Fibrosis. It targets the CFTR protein and has potential therapeutic applications in Congenital Disorders, Digestive System Disorders, and Respiratory Diseases. Further research and clinical trials are needed to determine the drug's efficacy and safety profile.

图形用户界面, 文本, 应用程序

描述已自动生成

The primary endpoint achieved by FASENRA in the Phase III MANDARA trial for eosinophilic granulomatosis with polyangiitis
Latest Hotspot
4 min read
The primary endpoint achieved by FASENRA in the Phase III MANDARA trial for eosinophilic granulomatosis with polyangiitis
17 September 2023
Positive high-level results from AstraZeneca's MANDARA Phase III study revealed that FASENRA(benralizumab)
Read →
Nemesis of Hypercholesterolemia - CETP inhibitors
Nemesis of Hypercholesterolemia - CETP inhibitors
17 September 2023
CETP, or Cholesteryl Ester Transfer Protein, plays a crucial role in lipid metabolism within the human body.
Read →
MBX Biosciences declares encouraging data from a Phase 1 Multiple Ascending Dose study for MBX 2109
Latest Hotspot
3 min read
MBX Biosciences declares encouraging data from a Phase 1 Multiple Ascending Dose study for MBX 2109
17 September 2023
MBX Biosciences, Inc. released favorable outcomes from the Phase 1 trial's multiple ascending dose section for MBX 2109.
Read →
Star of transcriptional pathway potential: CDK9 inhibitor
Star of transcriptional pathway potential: CDK9 inhibitor
17 September 2023
CDK9, also known as cyclin-dependent kinase 9, plays a crucial role in the regulation of gene expression and cell cycle progression in the human body.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.